MINNEAPOLIS--(BUSINESS WIRE)--Reflecting its commitment to patient safety and ongoing medical research, Medtronic, Inc. (NYSE:MDT) has announced that it will begin a new, large-scale clinical trial focusing on the safety of drug-eluting stents (DES). The PROTECT study will be the largest randomized stent trial ever conducted to assess and compare key safety measures of two drug-eluting stents. The trial will compare the Medtronic Endeavor® zotarolimus-eluting coronary stent system and the Johnson & Johnson Cypher® sirolimus-eluting stent.
